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Mammals encode proteins that inhibit viral replication at
the cellular level. In turn, certain viruses have evolved
genes that can functionally counteract these intrinsic
restrictions. Human CD317 (BST-2/tetherin) was recently
identified as a restriction factor that blocks release of HIV-
1 from the cell surface and can be overcome by HIV-1
Vpu. Here, we show that mouse and rat CD317 potently
inhibit HIV-1, but are resistant to Vpu. To promote virus
release, Vpu depletes cellular pools of human CD317, but
not of the rodent orthologs, by accelerating its degrada-
tion via the 20S proteasome. Importantly, HIV-1 down-
regulates surface-exposed CD317 and depletes
endogenous pools of the restriction factor in infected
human T-cells in a Vpu-dependent manner. Distinct
mutants of CD317 indicate that also degradation-inde-
pendent abilities of Vpu contribute to its ability to pro-
mote virus release. Interspecies-chimeras of CD317 reveal
that the rodent-specific resistance and human-specific
sensitivity to Vpu antagonism have a complex genetic
basis involving all three major structural domains of the
restriction factor. In rodent cells, knock-down of endog-
enous CD317 enhances HIV release and accelerates MLV
spread, suggesting that CD317 contributes to the control
of retroviral pathogenesis. Thus, HIV-1 Vpu suppresses the
expression of the CD317 antiviral factor in infected
human cells, and the species-specific resistance to Vpu
antagonism may guide the advancement of small animal
models of HIV infection.
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